Form 4: Jade Biosciences Grants Equity to CSO Andrew King

Jade Biosciences, Inc. disclosed equity grants to Chief Scientific Officer Andrew James King, including restricted stock units and stock options.

Summary

• Andrew James King, Chief Scientific Officer and Head of Research and Development at Jade Biosciences, Inc. (JBIO), was granted equity awards.
• On February 12, 2026, King acquired 41,250 restricted stock units (RSUs).
• These RSUs will vest in four equal annual installments, starting on February 15, 2027, subject to continued service.
• King also acquired 247,500 stock options with an exercise price of $14.81 per share.
• These stock options have an expiration date of February 11, 2036.
• The options will vest 1/4 on February 15, 2027, with the remainder vesting in equal monthly installments over the subsequent three years, subject to continued service.
• Following these transactions, King directly beneficially owns 386,113 shares of common stock and 247,500 stock options.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive disclosure, reflecting standard executive compensation practices aimed at retaining and incentivizing key scientific leadership, which is generally beneficial for long-term company stability and innovation.

Positives

• The equity grants align the interests of a key executive, Andrew James King, with those of shareholders.
• The vesting schedules for both RSUs and stock options incentivize long-term commitment and performance from the Chief Scientific Officer.
• The use of a Rule 10b5-1(c) plan indicates a pre-planned transaction, reducing concerns about opportunistic insider trading.

Negatives

• The issuance of new equity awards could lead to potential future dilution for existing shareholders upon vesting and exercise.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend several years into the future, indicating an expectation of continued service and long-term commitment from Andrew James King to Jade Biosciences, Inc.

Management Comments

• Andrew James King holds the title of Chief Scientific Officer & Head of Research and Development.

Industry Context

StockSavvy.ai notes that equity grants, such as restricted stock units and stock options, are standard components of executive compensation packages across the biotechnology and pharmaceutical industries. These grants are designed to attract, retain, and incentivize key talent by aligning their financial interests with the long-term performance of the company and its shareholders. The structure of these grants, with multi-year vesting schedules, is typical for senior leadership roles.

Comparison to Industry Standards

• The use of both RSUs and stock options is a common practice in executive compensation, similar to packages offered by companies like Moderna or BioNTech for their scientific leadership, aiming to balance immediate retention with long-term performance incentives.
• The multi-year vesting schedules (up to four years for RSUs and a similar period for options) are consistent with industry benchmarks for senior executive equity awards, ensuring sustained commitment.
• An exercise price of $14.81 for stock options is typical for grants made at or near the market price on the grant date, providing upside potential tied to future stock appreciation.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution from the exercise of options and vesting of RSUs, but also benefit from incentivized management focused on long-term value creation.
• Employees: May signal stability and commitment from senior leadership, potentially boosting morale.

Next Steps

• Vesting of 1/4 of the restricted stock units on February 15, 2027, and annually thereafter for three more years.
• Vesting of 1/4 of the stock options on February 15, 2027, with the remaining 3/4 vesting in equal monthly installments over the subsequent three years.

Key Dates

Keywords

Jade Biosciences, JBIO, Andrew James King, Chief Scientific Officer, CSO, Stock Options, Restricted Stock Units, RSUs, Equity Grant, Insider Transaction, Form 4, Executive Compensation, Rule 10b5-1